JPMorgan lowered the firm’s price target on Xencor (XNCR) to $18 from $20 and keeps an Overweight rating on the shares following the Q3 report.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
- Xencor Reports Improved Q3 2025 Financial Results
- Xencor’s Promising Clinical Updates and Strong Efficacy Support Buy Rating
- Promising Developments in Xencor’s Oncology and Autoimmune Pipelines Justify Buy Rating
- Xencor reports Q3 EPS (8c), consensus (70c)
- Beaten Down by 35%-Plus: Analysts Say These 2 Oversold Stocks Are Poised to Turn the Corner